Search Results - "Krebs, Annetta"

Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer by WELLS, Samuel A, GOSNELL, Jessica E, GAGEL, Robert F, MOLEY, Jeffrey, PFISTER, David, SOSA, Julie A, SKINNER, Michael, KREBS, Annetta, VASSELLI, James, SCHLUMBERGER, Martin

“…PURPOSE There is no effective therapy for patients with distant metastasis of medullary thyroid carcinoma (MTC). Activating mutations in the RET proto-oncogene…”
Get full text

AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors by Plimack, Elizabeth R., LoRusso, Patricia M., McCoon, Patricia, Tang, Weifeng, Krebs, Annetta D., Curt, Gregory, Eckhardt, S. Gail

“…Background. AZD1480 is a novel agent that inhibits Janus‐associated kinases 1 and 2 (JAK1 and JAK2). The primary objective of this phase I study was to…”
Get full text

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2 by HERBST, Roy S, GIACCONE, Giuseppe, WOLF, Michael K, KREBS, Annetta D, AVERBUCH, Steven D, OCHS, Judith S, GROUS, John, FANDI, Abderrahim, JOHNSON, David H, SCHILLER, Joan H, NATALE, Ronald B, MILLER, Vincent, MANEGOLD, Christian, SCAGLIOTTI, Giorgio, ROSELL, Rafael, OLIFF, Ira, REEVES, James A

“…Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase…”
Get full text

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer by HEYMACH, John V, PAZ-ARES, Luis, BONOMI, Philip D, HERBST, Roy S, KREBS, Annetta D, VASSELLI, James, JOHNSON, Bruce E, DE BRAUD, Filippo, SEBASTIAN, Martin, STEWART, David J, EBERHARDT, Wilfried E. E, RANADE, Anantbhushan A, COHEN, Graham, TRIGO, Jose Manuel, SANDIER, Alan B

“…Vandetanib is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling. The antitumor…”
Get full text

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials by BELL, Daphne W, LYNCH, Thomas J, KREBS, Annetta D, JOHNSON, David H, GIACCONE, Gmseppe, HERBST, Roy S, MANEGOLD, Christian, FUKUOKA, Masahiro, KRIS, Mark G, BASELGA, José, OCHS, Judith S, HABER, Daniel A, HASERLAT, Sara M, HARRIS, Patricia L, OKIMOTO, Ross A, BRANNIGAN, Brian W, SGROI, Dennis C, MUIR, Beth, RIEMENSCHNEIDER, Markus J, IACONA, Renee Bailey

“…Most cases of non-small-cell lung cancer (NSCLC) with dramatic responses to gefitinib have specific activating mutations in the epidermal growth factor…”
Get full text

DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study by Mross, Klaus, Fasol, Ulrike, Frost, Annette, Benkelmann, Robin, Kuhlmann, Jan, Büchert, Martin, Unger, Clemens, Blum, Hubert, Hennig, Jürgen, Milenkova, Tsveta P, Tessier, Jean, Krebs, Annetta D, Ryan, Anderson J, Fischer, Richard

“…Vandetanib is a once-daily oral inhibitor of VEGFR, EGFR and RET signaling pathways. In patients with advanced colorectal cancer and liver metastases, the…”
Get full text

Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer by Robinson, Bruce G., Paz-Ares, Luis, Krebs, Annetta, Vasselli, James, Haddad, Robert

“…Purpose: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinases that…”
Get full text

Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program by Govindan, Ramaswamy, Natale, Ronald, Wade, James, Herbst, Roy, Krebs, Annetta, Reiling, Richard, Hensing, Thomas, Wozniak, Antoinette, Belani, Chandra P., Kelly, Karen, Ochs, Judith

“…Chemotherapy (CT) is recommended in numerous clinical guidelines for advanced non-small cell lung cancer (NSCLC) and offers improved survival over best…”
Get full text